Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Although phencyclidine and ketamine are used to model a hypoglutamate theory of schizophrenia, their selectivity for NMDA receptors has been questioned. To determine the affinities of phencyclidine, ketamine, dizocilpine and LSD for the functional high-affinity state of the dopamine D2 receptor, D2High, their dissociation constants (Ki) were obtained on [3H]domperidone binding to human cloned dopamine D2 receptors. Phencyclidine had a high affinity for D2High with a Ki of 2.7 nM, in contrast to its low affinity for the NMDA receptor, with a Ki of 313 nM, as labeled by [3H]dizocilpine on rat striatal tissue. Ketamine also had a high affinity for D2High with a Ki of 55 nM, an affinity higher than its 3100 nM Ki for the NMDA sites. Dizocilpine had a Ki of 0.3 nM at D2High, but a Kd of 1.8 nM at the NMDA receptor. LSD had a Ki of 2 nM at D2High. Because the psychotomimetics had higher potency at D2High than at the NMDA site, the psychotomimetic action of these drugs must have a major contribution from D2 agonism. Because these drugs have a combined action on both dopamine receptors and NMDA receptors, these drugs, when given in vivo, test a combined hyperdopamine and hypoglutamate theory of psychosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a set of studies observed a high affinity of ketamine for the human D2 receptor expressed in Chinese Hamster Ovary cells (0.5 μM, Ki = 55 μM) and rat striatal 5-HT2 receptor (15 μM) (Kapur & Seeman, 2002; Seeman et al., 2005).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Seeman et al., 2005
Citations
Cites
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Jentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Goff, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 915
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Self-citationDopamine receptors and the dopamine hypothesis of schizophrenia
Seeman, P. (1987) · Synapse · doi:10.1002/syn.890010203 · Cited by 880
Self-citationLee, F. J. S., Xue, S., Pei, L., Vukusic, B., Chéry, N., Wang, Y., Wang, Y. T., Niznik, H. B., Yu, X.-M., & Liu, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00962-5 · Cited by 542
Köhler, C., Hall, H., Ögren, S.-O., & Gawell, L. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90778-6 · Cited by 505
Kapur, S., & Seeman, P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001093 · Cited by 459
Self-citationInteractive effects of subanesthetic ketamine and haloperidol in healthy humans
Krystal, J. H., D'Souza, D. C., Karper, L. P., Bennett, A., Abi-Dargham, A., Abi-Saab, D., Cassello, K., Bowers Jr., M. B., Vegso, S., Heninger, G. R., et al. (1999) · Psychopharmacology · doi:10.1007/s002130051049 · Cited by 243
Regulation of Dopamine D1 Receptor Function by Physical Interaction with the NMDA Receptors
Pei, L., Lee, F. J. S., Moszczynska, A., Vukusic, B., & Liu, F. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3922-03.2004 · Cited by 209
Research works printed but not linked: 1
- Van Rossum JM . The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Brill H, Cole J, Deniker P, Hippius H, Bradley PB (eds). Neuropsychopharmacology, Proceedings of the 5th Collegium Internationale Neuropsychopharmacologicum. Excerpta Medica Foundation: Amsterdam, 1967, pp 321–329.
Cited by
Belmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
“0 mM) for D2 receptors (D2Rs; Kapur and Seeman, 2002; Seeman et al., 2005) and to act as a partial agonist at these receptors (EC50 = 0.”
BackgroundSchwenk, E. S., Viscusi, E. R., Buvanendran, A., Hurley, R. W., Wasan, A. D., Narouze, S., Bhatia, A., Davis, F. N., Hooten, W. M., & Cohen, S. P. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000806 · Cited by 584
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
Role of central dopamine in pain and analgesia
Wood, P. B. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.5.781 · Cited by 370
Cohen, S. P., Bhatia, A., Buvanendran, A., Schwenk, E. S., Wasan, A. D., Hurley, R. W., Viscusi, E. R., Narouze, S., Davis, F. N., Ritchie, E. C., et al. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000808 · Cited by 350
Psychosis pathways converge via D2High dopamine receptors
Seeman, P., Schwarz, J., Chen, J.-F., Szechtman, H., Perreault, M., McKnight, G. S., Roder, J. C., Quirion, R., Boksa, P., Srivastava, L. K., et al. (2006) · Synapse · doi:10.1002/syn.20303 · Cited by 330
“As reviewed below, behavioral dopamine supersensitivity is invariably associated with an elevation in D2High, that is, an elevation in the proportion of dopamine D2 receptors in the state of high affinity for dopamine (Seeman et al., 2005a).”
BackgroundMethodInfluentialSelf-citationDopaminergic Control of Sleep–Wake States
Dzirasa, K., Ribeiro, S., Costa, R., Santos, L. M., Lin, S.-C., Grosmark, A., Sotnikova, T. D., Gainetdinov, R. R., Caron, M. G., & Nicolelis, M. A. L. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1767-06.2006 · Cited by 319
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01093-2 · Cited by 271
Kokkinou, M., Ashok, A. H., & Howes, O. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.190 · Cited by 247
Wood, P. B., Patterson, J. C., Sunderland, J. J., Tainter, K. H., Glabus, M. F., & Lilien, D. L. (2007) · The Journal of Pain · doi:10.1016/j.jpain.2006.05.014 · Cited by 245
Ketamine for Treatment-Resistant Unipolar Depression: Current Evidence
Mathew, S. J., Shah, A., Lapidus, K., Clark, C., Jarun, N., Ostermeyer, B., & Murrough, J. W. (2012) · CNS Drugs · doi:10.2165/11599770-000000000-00000 · Cited by 238
“Of note, the potency of ketamine at D2 receptors (Ki 55 nM) has been reported as higher than for NMDA receptors (Ki 3100 nM) on human receptors expressed in cultured hamster cells.([49]) D2 receptor messenger RNA expression is also induced by ketamine.”
BackgroundPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Paparelli, A., Di Forti, M., Morrison, P. D., & Murray, R. M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00001 · Cited by 216
“In 1983 Anis and colleagues showed that ketamine and phencyclidine selectively reduce responses of central neurons acting at the N-methyl-d-aspartate (NMDA) receptor (Anis et al., 1983; Seeman and Tallerico, 2005).”
BackgroundCohen, S. P., Liao, W., Gupta, A., & Plunkett, A. (2011) · Advances in Psychosomatic Medicine · doi:10.1159/000324071 · Cited by 200
Dopamine D2 Receptors as Treatment Targets in Schizophrenia
Seeman, P. (2010) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.4.1.5 · Cited by 193
Self-citationCunningham, M. O., Hunt, J., Middleton, S., LeBeau, F. E. N., Gillies, M. G., Davies, C. H., Maycox, P. R., Whittington, M. A., & Racca, C. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5054-05.2006 · Cited by 188
“In addition, LPA1 receptor knock-out mice show many neurochemical changes associated with postmortem analysis of brains from schizophrenics (Roberts et al., 2005), and ketamine models both the hyperdopamine and hypoglutamate putative mechanisms of schizophrenia (Seeman et al., 2005).”
BackgroundMechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
“In vitro receptor binding studies show that ketamine has very similar affinity to NMDARs and the high-affinity state of the D2 receptors (where it works as an antagonist) and a slightly lower affinity to 5-HT2 receptors (Kapur and Seeman, 2001, 2002; Seeman and Kapur, 2003; Seeman et al., 2005).”
BackgroundTowards understanding the schizophrenia code: an expanded convergent functional genomics approach
Le‐Niculescu, H., Balaraman, Y., Patel, S., Tan, J., Sidhu, K., Jerome, R. E., Edenberg, H. J., Kuczenski, R., Geyer, M. A., Nurnberger, J. I., et al. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30481 · Cited by 137
“PCP may act not only through NMDA receptor antagonism, but also through D2 receptor agonism, consistent with both hyperdopamine and hypoglutamate theories of psychosis [Seeman et al., 2005].”
Role of ketamine for analgesia in adults and children
Urman, R., Vadivelu, N., Schermer, E., Kodumudi, V., Belani, K. G., & Kaye, A. (2015) · Journal of Anaesthesiology Clinical Pharmacology · doi:10.4103/0970-9185.168149 · Cited by 152
“[13] Other in vitro studies have also demonstrated that ketamine has anti-inflammatory effects as it reduces tumor necrosis factor alpha, interleukin-6 (IL-6) and IL-8 levels, and also suppresses NF-KB expression which has a supposedly pivotal role in pro-inflammatory response.”
Backgroundd-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology
De Gregorio, D., Comai, S., Posa, L., & Gobbi, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111953 · Cited by 123
“also demonstrated that LSD and phencyclidine induce the incorporation of [35S]GTPγS into the inhibitory G protein (Gi) coupled to D2 receptors in homogenates of rat brain striatum [56].”
BackgroundMemantine agonist action at dopamine D2High receptors
Seeman, P., Caruso, C., & Lasaga, M. (2008) · Synapse · doi:10.1002/syn.20472 · Cited by 120
“It is possible, for example, that the properties of memantine may be similar to those of phencyclidine and ketamine which have similar potencies for the NMDA receptor and the high-affinity state of the dopamine D2 receptor (Kapur and Seeman, 2001; Seeman and Lasaga, 2005; Seeman et al., 2005).”
Self-citationDevelopmental neurotoxicity of ketamine in pediatric clinical use
Dong, C., & Anand, K. J. S. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2013.03.030 · Cited by 121
Nijs, J., Meeus, M., Van Oosterwijck, J., Roussel, N., De Kooning, M., Ickmans, K., & Matic, M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.547475 · Cited by 117
“Of relevance is the crucial role that NMDA-receptor activation plays in tolerance to the analgesic effects of narcotics, dependence on narcotics and narcotic-induced thermal hyperalgesia (for a review, see [62]).”
InfluentialCan, A., Zanos, P., Moaddel, R., Kang, H. J., Dossou, K. S. S., Wainer, I. W., Cheer, J. F., Frost, D. O., Huang, X.-P., & Gould, T. D. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235838 · Cited by 115
“5 mM) for DA D2-type receptors in vitro (Kapur and Seeman, 2002; Seeman et al., 2005), which was not identified in our study (Table 1).”
BackgroundRubio, J. M., Schoretsanitis, G., John, M., Tiihonen, J., Taipale, H. T., Guinart, D., Malhotra, A. K., Correll, C. U., & Kane, J. M. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30264-9 · Cited by 125
Becker, S., & Schweinhardt, P. (2011) · Pain Research and Treatment · doi:10.1155/2012/741746 · Cited by 134
“Ketamine is an interesting molecule: typically conceived as a NMDA receptor antagonist, it has recently been demonstrated to act mainly as a D2 dopamine receptor agonist in low doses [114].”
BackgroundDe Gregorio, D., Posa, L., Ochoa-Sanchez, R., McLaughlin, R., Maione, S., Comai, S., & Gobbi, G. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.022 · Cited by 110
Cortical Oscillations in Health and Disease
Traub, M., & Whittington, P. (2010) · doi:10.1093/acprof:oso/9780195342796.001.0001 · Cited by 107
Stone, J. M., Erlandsson, K., Arstad, E., Squassante, L., Teneggi, V., Bressan, R. A., Krystal, J. H., Ell, P. J., & Pilowsky, L. S. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1047-x · Cited by 103
“In addition, ketamine has direct effects at 5-hydroxytryptamine and high-affinity dopamine receptors, which have been suggested as being at least as potent as its effects at the NMDA receptor (Kapur and Seeman 2002; Seeman et al. 2005 ).”
BackgroundKokkinou, M., Irvine, E. E., Bonsall, D. R., Natesan, S., Wells, L. A., Smith, M., Glegola, J. A., Paul, E. J., Tossell, K., Veronese, M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0740-6 · Cited by 116
Blough, B. E., Landavazo, A., Decker, A. M., Partilla, J. S., Baumann, M. H., & Rothman, R. B. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3557-7 · Cited by 101
“Dopamine (DA) receptors (Marona-Lewicka et al. 2009; Marona-Lewicka et al. 2005; Seeman et al. 2005), the trace amine receptor (Bunzow et al.”
BackgroundMapping the central effects of ketamine in the rat using pharmacological MRI
Littlewood, C. L., Jones, N., O’Neill, M. J., Mitchell, S. N., Tricklebank, M. D., & Williams, S. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0344-0 · Cited by 101
“Under some circumstances, it indeed appears to have a greater affinity for D2 receptors when at a high-affinity state than for the PCP site on the NMDA receptor (Seeman et al. 2005).”
BackgroundLarge, C. H. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077712 · Cited by 94
“Most directly, there is evidence that some NMDA receptor antagonists might be agonists of dopamine D2 receptors (Seeman and Lasaga, 2005), and that this might be a common feature of psychotomimetics, including of course, amphetamine (Seeman et al., 2005).”
BackgroundKetamine: A Controversial Drug for Neonates
Bhutta, A. T. (2007) · Seminars in Perinatology · doi:10.1053/j.semperi.2007.07.005 · Cited by 107
Gregorio, D. D., Enns, J. P., Núñez, N. A., Posa, L., & Gobbi, G. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.07.008 · Cited by 103
Páleníček, T., Fujáková, M., Brunovský, M., Balíková, M., Horáček, J., Gorman, I., Tylš, F., Tislerova, B., Šóš, P., Bubeníková‐Valešová, V., et al. (2011) · Neuropsychobiology · doi:10.1159/000321803 · Cited by 99
Seeman, P., Guan, H., & Hirbec, H. (2009) · Synapse · doi:10.1002/syn.20647 · Cited by 84
Self-citationEffect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?
Hondebrink, L., Zwartsen, A., & Westerink, R. H. S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.022 · Cited by 80
Effects of sub-anesthetic doses of ketamine on rats' spatial and non-spatial recognition memory
Pitsikas, N., Boultadakis, A., & Sakellaridis, N. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.04.001 · Cited by 89
Do serotonin1–7 receptors modulate short and long-term memory?
Meneses, A. (2007) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2006.12.005 · Cited by 86
Increased dopamine D receptors in rats reared in social isolation
King, M. V., Seeman, P., Marsden, C. A., & Fone, K. C. F. (2009) · Synapse · doi:10.1002/syn.20624 · Cited by 73
“…of several genes associated with schizophrenia susceptibility, including those encoding catechol-O-methyltransferase, dopamine b-hydroxylase, trace amine-1 receptor, dopamine D4 receptor (Seeman et al., 2005b), dopamine transporter (DAT) and vesicular monoamine transporter 2 (Seeman et al., 2007a).”
InfluentialSelf-citationZamberlan, F., Sanz, C., Martínez Vivot, R., Pallavicini, C., Erowid, F., Erowid, E., & Tagliazucchi, E. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00054 · Cited by 71
“…been proposed that LSD binds first to 5-HT 2A receptors, leading to increased sensitivity of the dopaminergic system (primarily the D 2 and D 4 receptors; Seeman et al., 2005; Marona-Lewicka et al., 2009) resulting in a biphasic temporal effect (Freedman, 1984; Marona-Lewicka and Nichols, 2007).”
BackgroundWhat can we learn about schizophrenia from studying the human model, drug‐induced psychosis?
Murray, R. M., Paparelli, A., Morrison, P. D., Marconi, A., & Forti, M. D. (2013) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32177 · Cited by 83
The Role of Akt-GSK-3β Signaling and Synaptic Strength in Phencyclidine-Induced Neurodegeneration
Lei, G., Xia, Y., & Johnson, K. M. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301511 · Cited by 73
“On the other hand, Seeman and Lasaga, 2005 and Seeman et al, 2005 reported that PCP has a nanomolar affinity for the high-affinity state of the D2 receptor and thus could have a direct DA-like action on these cells.”
BackgroundTowards a Functional Understanding of PGO Waves
Gott, J. A., Liley, D. T. J., & Hobson, J. A. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00089 · Cited by 60
“However, the hypothesis currently remains open regarding the precise mechanisms by which these substances induce their hallucinatory visual effects, with some anticipating a more complex mechanism involving NMDA antagonism (Aghajanian and Marek, 2000), while others anticipate a dopaminergic mechanism instead (Marona-L…”
BackgroundLow doses of lysergic acid diethylamide (LSD) increase reward-related brain activity
Glazer, J. E., Murray, C. H., Nusslock, R., Lee, R., & de Wit, H. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01479-y · Cited by 61
5-HT2A/2C receptor blockade regulates progenitor cell proliferation in the adult rat hippocampus
Jha, S., Rajendran, R., Fernandes, K. A., & Vaidya, V. A. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.06.028 · Cited by 56
Fejgin, K., Pålsson, E., Wass, C., Svensson, L., & Klamer, D. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301587 · Cited by 55
“PCP is known to exert its effects not only through the NMDA receptor, but also by, acting as an agonist on dopamine receptors and by blocking dopamine reuptake (Rothman et al, 1989; Seeman et al, 2005; Seeman and Lasaga, 2005).”
BackgroundKolp, E., Friedman, H. L., University of Florida, Krupitsky, E., St. Petersburg State Pavlov Medical University, Jansen, K., Hospital, A., Sylvester, M., Young, M. S., University of South Florida, et al. (2014) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2014.33.2.84 · Cited by 54
Errico, F., D’Argenio, V., Sforazzini, F., Iasevoli, F., Squillace, M., Guerri, G., Napolitano, F., Angrisano, T., Maio, A. D., Keller, S., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.2 · Cited by 58
Effects of ketamine on psychomotor, sensory and cognitive functions relevant for driving ability
Giorgetti, R., Marcotulli, D., Tagliabracci, A., & Schifano, F. (2015) · Forensic Science International · doi:10.1016/j.forsciint.2015.04.024 · Cited by 55
du Jardin, K. G., Müller, H. K., Elfving, B., Dale, E., Wegener, G., & Sanchez, C. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.05.007 · Cited by 53
“Seeman et al., 2005; 8.”
Modulation of NMDA Receptor Activity in Fibromyalgia
Littlejohn, G. O., & Guymer, E. K. (2017) · Biomedicines · doi:10.3390/biomedicines5020015 · Cited by 58
“The function, structure and distribution of NMDARs through the brain, spinal cord and peripheral tissues show considerable heterogeneity, with variation of subunits, including NR1 and NR2 [14,16,17].”
BackgroundInfluentialThe neurophysiology of ketamine: an integrative review
McMillan, R. L., & Muthukumaraswamy, S. D. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0090 · Cited by 54
Behavioral genetic contributions to the study of addiction-related amphetamine effects
Phillips, T. J., Kamens, H. M., & Wheeler, J. M. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.10.008 · Cited by 59
Halje, P., Brys, I., Mariman, J. J., Cunha, C. D., Fuentes, R., & Petersson, P. (2019) · Journal of Neurophysiology · doi:10.1152/jn.00590.2018 · Cited by 52
“These authors also showed that the oscillation can be induced in L-DOPA-primed rats by independently activating either D1Rs or D2Rs (Dupre et al. 2016).”
BackgroundInhibition of glycogen synthase kinase-3 attenuates psychotomimetic effects of ketamine
Chan, M., Chiu, P., Lin, C.-Y., & Chen, H. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.01.024 · Cited by 49
“The primary mechanism of ketamine action is blockade of the NMDA receptor channel, although it also stimulates high affinity state of dopamine D2 receptors (Seeman and Kapur, 2003; Seeman et al., 2005).”
BackgroundJaster, A. M., Elder, H., Marsh, S. A., Revenga, M. D. L. F., Negus, S. S., & González‐Maeso, J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06092-x · Cited by 51
Janhunen, S. K., Svärd, H., Talpos, J., Kumar, G., Steckler, T., Plath, N., Lerdrup, L., Ruby, T., Haman, M., Wyler, R., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3954-6 · Cited by 43
“PCP has high affinity, at nanomolar range for the NMDA and sigma2 receptors, and low affinity, at micromolar range for the 5-HT transporter (Seeman et al. 2005; Roth et al. 2013).”
BackgroundResultInserra, A., Giorgini, G., Lacroix, S., Bertazzo, A., Choo, J. M., Markopolous, A., Grant, E., Abolghasemi, A., Gregorio, D. D., Flamand, N., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15977 · Cited by 44
“…through 5-hydroxytryptamine (5- HT; serotonin) receptors, including the 5-HT2A, 5-HT1A as well as AMPA receptors (de Gregorio et al., 2016, 2022; Seeman et al., 2005), neural and synaptic plasticity (Li et al., 2010; Ly et al., 2018), immune function (Szabo et al., 2014, 2016) and epigenetics…”
BackgroundSeeman, P. M., & Guan, H. (2008) · Synapse · doi:10.1002/syn.20561 · Cited by 45
Self-citationUsing the BOLD MR signal to differentiate the stereoisomers of ketamine in the rat
Littlewood, C. L., Cash, D., Dixon, A. L., Dix, S. L., White, C., O’Neill, M. J., Tricklebank, M. D., & Williams, S. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.05.022 · Cited by 44
“Ketamine has actually been reported to have a greater affinity for the high-affinity D2 receptor than the NMDA receptor (Seeman et al., 2005). and isoflurane is also known to inhibit the high affinity state of the D2 receptor (Seeman and Kapur, 2003).”
Effects of antipsychotic drugs on neurites relevant to schizophrenia treatment
Huang, X., & Song, X. (2018) · Medicinal Research Reviews · doi:10.1002/med.21512 · Cited by 47
1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances
Wallach, J. V., & Brandt, S. D. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_148 · Cited by 49
Ketamine: The final frontier or another depressing end?
Sial, O. K., Parise, E. M., Parise, L. F., Gnecco, T., & Bolaños‐Guzmán, C. A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112508 · Cited by 43
“Ketamine interacts with DA receptors, with high affinity for DA type 2 (D2) receptors (55 nM) [193]; however, Sketamine has a two- to three-fold higher affinity for D2 and NMDARs compared to the standard racemic mixture [178].”
BackgroundCilia, J., Hatcher, P., Reavill, C., & Jones, D. N. C. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077718 · Cited by 40
“…explained by the recent suggestion that the psychotomimetic effects of ketamine are due to a higher affinity for D2 receptors over NMDA receptors (Seeman et al., 2005) as haloperidol and risperidone, both of which have high affinity for D2 receptors (see Roth et al., 2004) failed to reverse the…”
BackgroundEger, E. I., Liao, M. Y., Laster, M. J., Won, A., Popovich, J., Raines, D. E., Solt, K., Dutton, R. C., Cobos, F. V., & Sonner, J. M. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000219019.91281.51 · Cited by 40
“Finally, MK-801 may be a “dirty” blocker, potently affecting other receptors such as dopamine (31).”
Fell, M. J., Perry, K. W., Falcone, J. F., Johnson, B. G., Barth, V., Rash, K. S., Lucaites, V. L., Threlkeld, P. G., Monn, J. A., McKinzie, D. L., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160598 · Cited by 39
“In a previous study, Seeman et al. (2005) have reported that other glutamatergic compounds, specifically, PCP, ketamine, and dizocilpine (MK-801), show relatively high affinity for D2 receptors when assayed using [ 3H]domperidone binding and act as full agonists when measured in vitro using a…”
MethodOlszewski, M., Dolowa, W., Matulewicz, P., Kasicki, S., & Hunt, M. J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.01.012 · Cited by 39
“, 1990) and dopamine D2 receptors (Seeman et al., 2005).”
Phencyclidine-Based New Psychoactive Substances
Wallach, J. V., & Brandt, S. D. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_124 · Cited by 42
Kotermanski, S. E., Johnson, J. W., & Thiels, E. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.05.005 · Cited by 46
“…acts with much higher affinity than ketamine at α7 nicotinic acetylcholine receptors (Aracava et al., 2005, Coates and Flood, 2001, Maskell et al., 2003), whereas ketamine acts with much higher affinity than memantine at D2High dopamine receptors (Seeman et al., 2008, Seeman et al., 2005).”
BackgroundGLT‐1 expression and Glu uptake in rat cerebral cortex are increased by phencyclidine
Fattorini, G., Melone, M., Bragina, L., Candiracci, C., Cozzi, A., Pellegrini-Giampietro, D. E., Torres-Ramos, M., Pérez‐Samartín, A., Matute, C., & Conti, F. (2008) · Glia · doi:10.1002/glia.20700 · Cited by 36
“The possibility that administration of high doses of PCP for 7 days activates other mechanisms (Seeman et al., 2005) or that PCP interacts with GLT-1 cannot however be discounted.”
BackgroundAn Elephant Among Us: The Role of Dopamine in the Pathophysiology of Fibromyalgia
Wood, P. B., & Holman, A. J. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.080583 · Cited by 39
Finnema, S. J., Halldin, C., Bang‐Andersen, B., Gulyás, B., Bundgaard, C., Wikström, H. V., & Farde, L. (2009) · Synapse · doi:10.1002/syn.20615 · Cited by 33
Differential Effects of Anaesthesia on the phMRI Response to Acute Ketamine Challenge
Hodkinson, D. J., de Groote, C., McKie, S., Deakin, J. F. W., & Williams, S. R. (2012) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2012/1412 · Cited by 35
“However, NMDA ligands such as PCP and ketamine may have actions on other neurotransmitters at high doses potentially limiting their usefulness as models of schizophrenia (Kapur et al., 2002; Seeman et al., 2005).”
Hillhouse, T. M., Porter, J. H., & Negus, S. S. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3451-3 · Cited by 33
“Moreover, ketamine’s selectivity for NMDA receptors over other receptor types is modest (Hirota et al. 2002; Nishimura et al. 1998; Seeman et al. 2005; Smith et al. 1987), suggesting that ketamine may produce effects at targets other than NMDA receptors.”
BackgroundSinha, J. K., Trisal, A., Ghosh, S., Gupta, S., Singh, K. K., Han, S. S., Mahapatra, M., Abomughaid, M. M., Abomughayedh, A. M., Almutary, A. G., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102211 · Cited by 32
Wood, P. B. (2006) · Journal of Pain · doi:10.1016/j.jpain.2006.01.457 · Cited by 32
Bygrave, A. M., Kilonzo, K., Kullmann, D. M., Bannerman, D. M., & Kätzel, D. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00835 · Cited by 43
Okada, M., Kawano, Y., Fukuyama, K., Motomura, E., & Shiroyama, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217951 · Cited by 32
Hillhouse, T. M., & Porter, J. H. (2013) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000014 · Cited by 34
“Seeman et al. (2005) found similar results (183-fold difference) when comparing binding affinities in human cloned dopamine D2 receptors, with ketamine having a significantly lower binding affinity than MK-801.”
ResultRole of Major NMDA or AMPA Receptor Subunits in MK‐801 Potentiation of Ethanol Intoxication
Palachick, B., Chen, Y., Enoch, A. J., Karlsson, R., Mishina, M., & Holmes, A. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00715.x · Cited by 32
“Although seemingly unlikely, this cannot be fully excluded given the drug’s known effects on for example norepinephrine (Snell et al., 1988), dopamine (Seeman et al., 2005) and acetylcholine (Ramoa et al., 1990) function.”
BackgroundDopamine partial agonist action of (−)OSU6162 is consistent with dopamine hyperactivity in psychosis
Seeman, P. M., & Guan, H. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.016 · Cited by 30
“The method for the incorporation of [S]-GTP-γ-S into the cloned dopamine D2Long receptor-expressing CHO cells has also been previously described (Seeman et al., 2005).”
MethodSelf-citationNovel pharmacotherapy for fibromyalgia
Wood, P. B., Holman, A. J., & Jones, K. D. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.6.829 · Cited by 30
“Moreover, given the activity of ketamine as a dopamine D2 receptor agonist [30,31], it would seem that the capacity of ketamine to relieve FM pain also suggests a role for dopaminergic dysfunction.”
Backgroundvan de Loo, A. J. A. E., Bervoets, A. C., Mooren, L., Bouwmeester, N. H., Garssen, J., Zuiker, R., van Amerongen, G., van Gerven, J., Singh, J., der Ark, P. V., et al. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4706-6 · Cited by 29
“…psychomimetic effects includingmodulation of cognitive processes, emotional responses, memory, and learning (Aalto et al. 2005; Duan et al. 2013; Seeman et al. 2005) could be attributable to its activity on cholinergic systems (postanesthetic delirium) (Hustveit et al. 1995), memory learning…”
Seeman, P. M., Battaglia, G., Corti, C., Corsi, M., & Bruno, V. (2008) · Synapse · doi:10.1002/syn.20607 · Cited by 30
“In striatal homogenates from control mice, the proportion of D2 receptors in the high-affinity state for dopamine, D2High, was 16.2% 6 2.5% (mean 6 SE, n 5 5), in agreement with an average value of 19% 6 1% in striatal homogenates from mice or rats (Seeman et al., 2005b, 2006a,b) (Fig.”
BackgroundMethodInfluentialSelf-citationRoser, P., Haussleiter, I. S., Chong, H.-J., Maier, C., Kawohl, W., Norra, C., & Juckel, G. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2352-y · Cited by 29
“In particular, both psychostimulants have been found to exhibit agonistic properties at dopamine D2 receptors, leading to a hyperdopaminergic state ( Seeman et al. 2005, 2009 ).”
BackgroundDopamine partial agonist actions of the glutamate receptor agonists LY 354,740 and LY 379,268
Seeman, P. M., Caruso, C. M., & Lasaga, M. (2007) · Synapse · doi:10.1002/syn.20482 · Cited by 28
“their affinities for the NMDA receptor (Kapur and Seeman, 2002; Seeman and Lasaga, 2005; Seeman et al., 2005; but see Jordan et al., 2006).”
BackgroundMethodInfluentialSelf-citationKetamine for Pain Management: A Review of Literature and Clinical Application
Caruso, K., Tyler, D. J., & Lyden, A. (2021) · Orthopaedic Nursing · doi:10.1097/nor.0000000000000759 · Cited by 29
Jordan, S., Chen, R., Fernalld, R., Johnson, J. L., Regardie, K., Kambayashi, J., Tadori, Y., Kitagawa, H., & Kikuchi, T. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.04.026 · Cited by 27
Historical Overview: Introduction to the Dopamine Receptors
Seeman, P. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-333-6_1 · Cited by 39
“contribution to action of PCP, LSD, and ketamine Seeman et al. [ 92 ]”
BackgroundSelf-citationAmphetamine sensitization elevates CaMKIIß mRNA
Greenstein, R., Novak, G., & Seeman, P. (2007) · Synapse · doi:10.1002/syn.20429 · Cited by 26
“Furthermore, glutamate receptor agonists induce a very mild improvement in symptoms when used in the treatment of psychosis (Seeman et al., 2005a).”
BackgroundResultInfluentialSelf-citationAllen, R. M., Carelli, R. M., Dykstra, L., Suchey, T. L., & Everett, C. V. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.086355 · Cited by 23
“Recently, several high-affinity channel blockers, such as 1-(1-phenylcyclohexyl)piperidine (phencyclidine), ketamine, and dizocilpine, have been shown to bind with high affinity to the highaffinity state of the dopamine D2 receptor (D2; Seeman et al., 2005).”
BackgroundInfluentialTanqueiro, S. R., Mouro, F. M., Ferreira, C. B., Freitas, C. F., Fonseca‐Gomes, J., do Couto, F. S., Sebastião, A. M., Dawson, N., & Diógenes, M. J. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211008560 · Cited by 24
Ketamine's schizophrenia-like effects are prevented by targeting PTP1B
Qin, Z., Zhang, L., ZASLOFF, M. A., Stewart, A. F. R., & Chen, H. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105397 · Cited by 25
Tsukada, H., Ohba, H., Nishiyama, S., & Kakiuchi, T. (2010) · Synapse · doi:10.1002/syn.20845 · Cited by 24
Li, J., Ren, H., Hé, Y., Li, Z., Ma, X., Liu, Y., Ouyang, L., Zhou, J., Wang, D., Li, C., et al. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.553269 · Cited by 27
“First, some studies have found that ketamine also has a high affinity for D2 receptors (54, 55), while a recent study found that ketamine has no affinity for D2 receptors (56).”
BackgroundThe dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2 High receptors
Seeman, P. M., Tokita, K., Matsumoto, M., Matsuo, A., Sasamata, M., & Miyata, K. (2009) · Synapse · doi:10.1002/syn.20663 · Cited by 22
“HCl on the incorporation of [35S]GTP-g-S was measured as previ- 931D2HIGH TARGET FOR DOPAMINE STABILIZER Synapse ously described (Seeman et al., 2005).”
MethodSelf-citation
Metadata
- Authors
- Seeman, P., Ko, F., & Tallerico, T.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Seeman, P
- ORCID
- Seeman, P
- Venue
- Molecular Psychiatry
- Published
- 2005-04-26
- Volume
- 10
- Issue
- 9
- Pages
- 877-883
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2024217117
- Cited by
- 200
- References
- 38
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 8 · 2023: 4 · 2022: 4 · 2021: 8 · 2020: 10 · 2019: 8 · 2018: 11 · 2017: 9 · 2016: 5 · 2015: 14 · 2014: 5 · 2013: 9 · 2012: 9
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- dopamine D2 receptor, NMDA receptor, phencyclidine, ketamine, LSD, MK-801, psychotomimetics, schizophrenia, receptor binding affinity, dissociation constant
- MeSH terms
- Animals, Cloning, Molecular, Corpus Striatum, Domperidone, Dopamine, Cricetinae, Ketamine, Kinetics, Lysergic Acid Diethylamide, Membrane Glycoproteins, Nerve Tissue Proteins, Phencyclidine, Dizocilpine Maleate, CHO Cells, Receptors, Dopamine D2, Excitatory Amino Acid Antagonists, Membrane Transport Proteins, Dopamine Plasma Membrane Transport Proteins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.